Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer - Top-Institutions - MDSpire

Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved the antibody-drug conjugate sacituzumab govitecan for first-line treatment of metastatic triple-negative breast cancer.

  • By

  • June 24, 2026

  • 4 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

Original Source(s)

Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer

  • by

  • June 24, 2026

Related Content

ASCO26: Jennifer Ligibel, MD, BWEL

Dana-Farber Cancer Institute's Dr. Jennifer Ligibel shared updated results from the BWEL study showing a weight loss intervention led to significantly better physical function, global physical and mental health, and symptom in patients with early breast cancer.

  • July 1, 2026

  • 1 min
ESMO Breast Cancer 2026 Highlights: SERENA-6

Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH discuss results from the SERENA-6 trial, which were presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

  • 1 min
Two Dana-Farber Hematologists Receive Top Honors From the American Society of Hematology

The American Society of Hematology is recognizing 11 distinguished hematologists with its most prestigious awards and named lectures, honoring transformative contributions that have advanced research, patient care, and education in blood disorders. Two of this year’s honorees are from Dana-Farber Cancer Institute: Benjamin L. Ebert, MD, PhD, and Scott A. Armstrong, MD, PhD.

  • by

  • June 23, 2026

  • 4 min